4.5 Article

MICRORNA-922 PROMOTES TAU PHOSPHORYLATION BY DOWNREGULATING UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 (UCHL1) EXPRESSION IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE

Journal

NEUROSCIENCE
Volume 275, Issue -, Pages 232-237

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2014.06.013

Keywords

miR-922; UCHL1; phosphorylated tau; Alzheimer's disease

Categories

Funding

  1. National Program of Basic Research of China [2010CB945200, 2011CB504104]
  2. National Natural Science Fund [81371407, 91332107]
  3. twelfth Five-year National Science and Technology Support Program [2012BA110803]

Ask authors/readers for more resources

Decreased levels of soluble ubiquitin carboxyterminal hydrolase L1 (UCHL1) have been reported in the brains of sporadic Alzheimer's disease (AD) patients, and the introduction of UCHL1 rescued the synaptic and cognitive function of AD model mice. Obviously, a reduction in the levels of UCHL1 may play a role in the pathogenesis of AD. However, the mechanisms underlying the regulation of UCHL1 levels in AD have not been fully elucidated. MicroRNAs (miRs) have been shown to participate in the process of AD. In our study, we discovered that microRNA-922 decreased the levels of UCHL1. Neurofibrillary tangles (NFTs) mainly consisting of the hyperphosphorylated microtubule-associated protein tau are the defining pathological features of AD. In the present study, we found the levels of UCHL1 affected the levels of phosphorylated tau: the phosphorylated tau levels increased after knockdown of UCHL1 expression, and the phosphorylated tau levels decreased when UCHL1 was over-expressed. Furthermore, overexpression of microRNA-922 increased the phosphorylated tau levels. In conclusion, miR-922 increasing the levels of phosphorylated tau by regulating UCHL1 levels contributed to the pathogenesis of AD. Our study partly explained one of the mechanisms underlying the downregulation of UCHL1 levels in AD patients and could enrich the content of tau pathology in the pathogenesis of AD. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available